Rashid M, et al. - Via performing a systematic review of descriptive studies, researchers identified and critically assessed all case reports on levetiracetam (LEV)-induced cutaneous adverse drug reactions (CADRs). They also reported possible clinical manifestations, management, and the treatment outcomes of the condition. They reviewed data from 24 studies, which included 25 individuals (age ranged from 40 weeks to 73 years). These individuals received between 500 mg/day to 3,000 mg/day of LEV. They noted the following drug reactions: eosinophilia and systemic symptoms syndrome, Steven-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, generalized hyperpigmentation, and leukocytoclastic vasculitis. According to the researchers, clinicians should be aware of potential LEV-induced CADRs to prevent any fatal medical conditions. In the management of the CADRs, immediate withdrawal of the drug and supporting care appeared to be effective.